sy-009
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2019 (NCT04119947)
Timeline
Indications
Mechanism of action
- SGLT1 proteinINHIBITOR
SLC5A1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05426018 | Phase 2 | Jul 1, 2022 | Yabao Pharmaceutical Group |
| NCT04345107 | Phase 1 | May 1, 2020 | Yabao Pharmaceutical Group |
| NCT04119947 | Phase 1 | Mar 1, 2019 | Peking University, Yabao Pharmaceutical Group |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Yabao Pharmaceutical Group | For profit | 3 | 3 | 2 | 2019 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2019 |
2 organizations
Page 1 / 1